This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Olanzapine in the Treatment of Anorexia Nervosa

This study has been completed.
Eli Lilly and Company
Information provided by:
Northwell Health Identifier:
First received: January 2, 2008
Last updated: January 11, 2008
Last verified: January 2008
This study compared 10 weeks of treatment with olanzapine versus placebo in adolescent females with anorexia nervosa-restricting type who were undergoing acute treatment on an inpatient unit or a day hospital program that specializes in the treatment of eating disorders.

Condition Intervention Phase
Anorexia Nervosa Drug: olanzapine Drug: placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pilot Study of the Efficacy of Olanzapine in the Treatment of Anorexias Nervosa

Resource links provided by NLM:

Further study details as provided by Northwell Health:

Primary Outcome Measures:
  • weight gain [ Time Frame: 10 weeks ]

Secondary Outcome Measures:
  • measures of psychiatric symptoms [ Time Frame: 10 weeks ]

Estimated Enrollment: 20
Study Start Date: June 2000
Estimated Study Completion Date: December 2004
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: olanzapine
flexibly dosed oral olanzapine 2.5 to 15 mg/day
Placebo Comparator: 2
matching placebo
Drug: placebo


Ages Eligible for Study:   12 Years to 23 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Females, ages 12-23

Exclusion Criteria:

  • Binge-purge type
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00592930

United States, New York
Schneider Children's Hospital
New Hyde Park, New York, United States, 11040
Sponsors and Collaborators
Northwell Health
Eli Lilly and Company
Principal Investigator: Vivian Kafantaris, M.D. Schneider Children's Hospital
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Vivian Kafantaris, M. D., North Shore- Long Island Jewish Health System Identifier: NCT00592930     History of Changes
Other Study ID Numbers: 99-04-072
Lilly F1D-US-X166
Study First Received: January 2, 2008
Last Updated: January 11, 2008

Keywords provided by Northwell Health:
anorexia nervosa, treatment, adolescents, olanzapine

Additional relevant MeSH terms:
Anorexia Nervosa
Signs and Symptoms, Digestive
Signs and Symptoms
Feeding and Eating Disorders
Mental Disorders
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents processed this record on September 19, 2017